To address clinical unmet needs and support
better human health, become one of the top
tier pharmaceutical companies in China.
Agility
Innovation
Be Reslistic
Collaboration
Ownership
R & D System
Huilun is devoted to the development of both generic to fulfil the unmet clinical needs.
R & D Platform
Preclinical Research Platform
Pharmaceutical Research Platform
Clinical Research Platform
R & D Team
We are proud to have a professional R&D team with deep insights into unmet clinical needs, marketing and industrial development of medicine.
R & D Achievements
Over 40 clinical trial permissions approved by CFDA
Over 20 drugs were applied for the
manufacturing licenses with 10+ approved Over 10 APIs passed review
R & D System
Huilun is devoted to the development of both generic to fulfil the unmet clinical needs.
More
R & D Platform
Preclinical Research Platform <br> Pharmaceutical Research Platform<br> Clinical Research Platform
More
R & D Team
We are proud to have a professional R&D team with deep insights into unmet clinical needs, marketing and industrial development of medicine.
More
R & D Achievements
Over 40 clinical trial permissions approved by CFDA<br> Over 20 drugs were applied for the<br> manufacturing licenses with 10+ approved Over 10 APIs passed review
More
2024年03月
07
醫(yī)藥代表信息備案公示
響應(yīng)《醫(yī)藥代表備案制管理辦法（試行）》的相關(guān)要求，現(xiàn)將上海匯倫醫(yī)藥股份有限公司現(xiàn)有醫(yī)藥代表的詳細(xì)備案信息進(jìn)行公示。
2023年04月
06
匯倫湖北原料藥生產(chǎn)基地項目機(jī)電安裝工程（罐區(qū)部分）
2022年08月
15
【藥聞速覽】
2020.10.27-2020.11.11國內(nèi)藥訊14條，2020.11.5國際藥訊1條，2020.10.27-2020.11.05標(biāo)準(zhǔn)公示13條。
